Home Cart Sign in  
Chemical Structure| 83881-51-0 Chemical Structure| 83881-51-0

Structure of Cetirizine
CAS No.: 83881-51-0

Chemical Structure| 83881-51-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Cetirizine, a second-generation antihistamine, is a major metabolite of hydroxyzine, and a racemic selective H1 receptor inverse agonist used in the treatment of allergies, hay fever, angioedema, and urticaria.

Synonyms: Cetirizine

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Cetirizine

CAS No. :83881-51-0
Formula : C21H25ClN2O3
M.W : 388.89
SMILES Code : O=C(COCCN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=C(Cl)C=C3)O
Synonyms :
Cetirizine
MDL No. :MFCD00800721
InChI Key :ZKLPARSLTMPFCP-UHFFFAOYSA-N
Pubchem ID :2678

Safety of Cetirizine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P332+P313-P337+P313-P362-P403+P233-P405-P501

Related Pathways of Cetirizine

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
rat peritoneal eosinophils 10^-6 to 10^-4 M 10 min To evaluate the effect of cetirizine on PAF-induced eosinophil chemotaxis, results showed that cetirizine failed to inhibit PAF-induced eosinophil chemotaxis. Br J Pharmacol. 1992 Jan;105(1):176-80.
POAH neurons 10 μM Cetirizine completely blocked histamine-induced Ca2+ responses in POAH neurons Br J Pharmacol. 2012 Jan;165(1):167-82.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Male Wistar rats Pleurisy model Intraperitoneal 5 to 30 mg/kg Single dose, 1 hour To evaluate the inhibitory effect of cetirizine on PAF- or compound 48/80-induced pleural eosinophil accumulation. Results showed that cetirizine dose-dependently inhibited eosinophil accumulation induced by PAF and compound 48/80, with ED50 values of 19 mg/kg and 14 mg/kg, respectively. Br J Pharmacol. 1992 Jan;105(1):176-80.
Male Wistar rats Pleurisy model Intrathoracic injection 5 and 15 μg/cavity 5 minutes (i.t.) before pretreatment To evaluate the inhibitory effect of cetirizine on PAF- or compound 48/80-induced pleural eosinophil accumulation. Results showed that intrathoracic administration of low doses of cetirizine (5 and 15 μg/cavity) also significantly inhibited eosinophil accumulation. Br J Pharmacol. 1992 Jan;105(1):176-80.
Guinea pigs Non-immunized guinea pigs receiving platelets from immunized animals Intravenous injection 10-30 mg/kg Administered 1 hour before antigen challenge Cetirizine dose-dependently inhibited platelet-dependent leucopenia, with the highest dose achieving complete inhibition. Br J Pharmacol. 1991 Jun;103(2):1520-4
Rats Sprague-Dawley rats Intracerebroventricular infusion 10μM/100μL 10 hours Cetirizine significantly increased non-REM sleep, abolished REM sleep, and decreased wakefulness for more than 10 h Br J Pharmacol. 2012 Jan;165(1):167-82.
Balb/C mice Ovalbumin-induced peritonitis model Subcutaneous injection 15-30 mg/kg 1 hour before and 6 hours after Cetirizine significantly reduced ovalbumin-induced eosinophil accumulation, whereas terfenadine was ineffective, suggesting that the effect of cetirizine was not related to the inhibition of the H1 receptor effects of histamine. Br J Pharmacol. 1993 Oct;110(2):917-24
Guinea-pigs Ovalbumin-sensitized guinea-pig paw oedema model Subcutaneous injection 20 mg/kg Single dose, measured after 30 minutes To evaluate the effect of cetirizine on ovalbumin-induced paw oedema, results showed cetirizine did not inhibit the oedema Br J Pharmacol. 1994 May;112(1):111-6
Guinea pigs OA-sensitized guinea pigs Intraperitoneal injection 10 mg/kg Single dose, 1 hour before To evaluate the effect of cetirizine on OA-induced bronchoconstriction. Cetirizine significantly inhibited OA-induced bronchoconstriction (70% inhibition). Br J Pharmacol. 2012 Jul;166(6):1822-32
Rats Anesthetized rat dural blood flow model Intravenous injection 50 mg/kg Single dose To investigate the effect of cetirizine on histamine-induced increases in dural blood flow. Results showed that i.v. cetirizine significantly reduced the flow increases induced by i.v. histamine administration. Br J Pharmacol. 2002 Nov;137(6):874-80

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02372604 Chronic Spontaneous Urticaria Phase 3 Completed - -
NCT01567501 Fed Phase 1 Completed - India ... More >> Accutest Research Lab (I) Pvt. Ltd. Ahmedabad, Gujarat, India, 380054 Less <<
NCT03555890 Rhinitis Phase 1 Completed - Japan ... More >> GSK Investigational Site Fukuoka, Japan, 812-0025 Less <<
NCT02394119 Nephrotic Syndrome Phase 2 Recruiting May 2019 Italy ... More >> IRCCS Istituto Giannina Gaslini Recruiting Genoa, Italy/GE, Italy, 16147 Contact: Gian Marco Ghiggeri, MD    0039 010 5636 2419    gmarcoghiggeri@ospedale-gaslini.ge.it    Principal Investigator: Gian Marco Ghiggeri, MD          Sub-Investigator: Alice Bonanni, MD Less <<
NCT02394106 Nephrotic Syndrome Phase 2 Recruiting March 2018 Italy ... More >> IRCCS Istituto Giannina Gaslini Recruiting Genoa, Italy/GE, Italy, 16147 Contact: Gian Marco Ghiggeri, MD    0039 010 5636 2419    gmarcoghiggeri@ospedale-gaslini.ge.it    Principal Investigator: Gian Marco Ghiggeri, MD          Sub-Investigator: Alice Bonanni, MD Less <<
NCT02771249 Healthy Volunteers Phase 1 Recruiting December 31, 2019 United States, Maryland ... More >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)    800-411-1222 ext TTY8664111010    prpl@cc.nih.gov Less <<
NCT00557284 - Completed - -
NCT00001910 - Completed - United States, Maryland ... More >> National Institute of Allergy and Infectious Diseases (NIAID) Bethesda, Maryland, United States, 20892 Less <<
NCT03590912 Otitis Media With Effusion Phase 4 Not yet recruiting September 2019 Nepal ... More >> Lumbini Medical College Tansen, Palpa, Nepal, 32500 Less <<
NCT00557284 Atopic Dermatitis Phase 4 Completed - United States, Colorado ... More >> 1st Allergy & Clinical Research Centers Centennial, Colorado, United States, 80112 1st Allergy & Clinical Research Centers Thornton, Colorado, United States, 80229 Less <<
NCT02873364 Urticaria Phase 3 Unknown January 2017 Iran, Islamic Republic of ... More >> Shiraz University of Medical Sciences Recruiting Shiraz, Fars, Iran, Islamic Republic of Contact: Keramatallah Jahanshahi, MD    +989177416523    kjahanshahi91@gmail.com Less <<
NCT03523221 Mild -Moderate Anaphylaxis - S... More >>ymptoms That Affect the Skin With Cardiovascular, Respiratory or Gastrointestinal Involvement, But no Signs of Hypotension ,Laryng Less << Phase 1 Recruiting August 2020 Qatar ... More >> Hamad Medical Corporation Recruiting Doha, Qatar, 3050 Contact: Rafah Sayyed, MD    +97455747045    ralsayyed@hamad.qa Less <<
NCT03296358 Urticaria All... More >>ergy Less << Not Applicable Recruiting October 31, 2019 Thailand ... More >> Chulalongkorn Hospital Recruiting Pathum Wan, Bangkok, Thailand, 10600 Contact: Pakhawadee Palungwachira, Bachelor    66897704758    zaphyr_s@yahoo.com    Principal Investigator: Pakhawadee Palungwachira, Bachelor          Sub-Investigator: Katsara Vilaisri, Bachelor          Sub-Investigator: Klongwong Musikatavorn, Bachelor Less <<
NCT01451996 - Completed - -
NCT01451996 Healthy Phase 4 Completed - United States, Illinois ... More >> University of Chicago Chicago, Illinois, United States, 60637 Less <<
NCT02613910 Pemphigus Phase 3 Terminated(Novartis has acquir... More >>ed the rights to ofatumumab and terminated the OPV116910 and OPV117059 studies. This decision is not linked to any safety consideration.) Less << - United States, California ... More >> GSK Investigational Site Los Angeles, California, United States, 90045 United States, Michigan GSK Investigational Site Ann Arbor, Michigan, United States, 48103 Less <<
NCT02646904 Allergic Rhinitis Phase 4 Completed - Italy ... More >> Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council Palermo, Sicily, Italy, 90146 Institute of Biomedicine and Molecular Immunology, IBIM Palermo, Italy, 90146 Less <<
NCT02613910 - Terminated(Novartis has acquir... More >>ed the rights to ofatumumab and terminated the OPV116910 and OPV117059 studies. This decision is not linked to any safety consideration.) Less << - -
NCT01985789 Asthma Phase 4 Completed - Canada, Saskatchewan ... More >> University of Saskatchewan Saskatoon, Saskatchewan, Canada, S7N 0W8 Less <<
NCT02583594 Progressive Multiple Sclerosis Phase 1 Active, not recruiting April 2021 Spain ... More >> Investigational Site Number 724001 Barcelona, Spain, 08035 Less <<
NCT01902836 Childhood Atopic Dermatitis Phase 2 Completed - Mexico ... More >> Hospital Infantil de México, Fedérico Gómez México, DF, Mexico, 06720 Less <<
NCT01981499 Migraine Phase 1 Terminated(The trial was prema... More >>turely terminated on 01April2014 due to safety concerns.) Less << - United States, Minnesota ... More >> Pfizer Investigational Site St. Paul, Minnesota, United States, 55114 Less <<
NCT02024152 Acute Urticaria Phase 1 Completed - Canada, Quebec ... More >> Algorithme Pharma Montreal, Quebec, Canada Less <<
NCT01940393 Urticaria Phase 4 Completed - Colombia ... More >> Medellin Medellin, Antioquia, Colombia Less <<
NCT01241214 Seasonal Allergic Rhinitis Phase 2 Completed - United States, Texas ... More >> Clinical Investigative Site 7905 Austin, Texas, United States, 78731 Clinical Investigative Site 7907 Kerrville, Texas, United States, 78028 Clinical Investigative Site 7903 New Braunfels, Texas, United States, 78130 Clinical Investigative Site 7901 San Antonio, Texas, United States, 78229 Clinical Investigative Site 7902 San Antonio, Texas, United States, 78229 Clinical Investigative Site 7904 San Antonio, Texas, United States, 78229 Clinical Investigative Site 7906 San Antonio, Texas, United States, 78229 Less <<
NCT02535416 Healthy Phase 1 Completed - Australia, Queensland ... More >> QPharm, Pty Limited, Royal Brisbane Hospital Herston, Queensland, Australia, 4029 Less <<
NCT02535416 - Completed - -
NCT00561717 Seasonal Allergic Rhinitis Phase 4 Completed - Canada, Ontario ... More >> Kingston, Ontario, Canada, K7L 2V7 Less <<
NCT00517946 - Completed - United Kingdom ... More >> GSK Investigational Site London, United Kingdom, W1G 8HU Less <<
NCT01134328 - Completed - -
NCT01008592 - Terminated(Mediators of intere... More >>st were not consistently detectable with the analytical methods employed.) Less << - United States, North Carolina ... More >> Wake Forest University Health Sciences, Department of Dermatology Winston-Salem, North Carolina, United States, 27157 Less <<
NCT01318681 Seasonal Allergic Rhinitis ... More >> Driving Ability Cognition Less << Not Applicable Completed - Netherlands ... More >> Maastricht University Maastricht, Limburg, Netherlands, 62ooMD Less <<
NCT00533637 Allergic Rhinitis Phase 2 Completed - Sweden ... More >> Department of Otorhinolaryngology, Lund University Hospital Lund, Sweden, SE-221 85 Less <<
NCT01484119 Seasonal Allergic Rhinitis Phase 3 Completed - United States, Texas ... More >> Clinical Investigative Site 7905 Austin, Texas, United States, 78731 Clinical Investigative Site 7907 Kerrville, Texas, United States, 78028 Clinical Investigative Site 7903 New Braunfels, Texas, United States, 78130 Clinical Investigative Site 7901 San Antonio, Texas, United States, 78229 Clinical Investigative Site 7902 San Antonio, Texas, United States, 78229 Clinical Investigative Site 7904 San Antonio, Texas, United States, 78229 Clinical Investigative Site 7906 San Antonio, Texas, United States, 78229 Less <<
NCT02935699 Acute Urticaria Phase 3 Recruiting April 2018 United States, Texas ... More >> City Doc Urgent Care center Recruiting Dallas, Texas, United States, 75209 Contact: Brook Jackson          Canada, Ontario Ottawa Hospital Recruiting Ottawa, Ontario, Canada, K1Y 4E9 Contact: Cathy Clement Less <<
NCT01068223 Histamine Induced Itch Phase 1 Completed - United Kingdom ... More >> Harrow, United Kingdom Less <<
NCT00610584 Seasonal Allergic Rhinitis Not Applicable Completed - Germany ... More >> Charité - Institute for Social Medicine Berlin, Germany, 10098 Less <<
NCT00291642 Rhinitis Alle... More >>rgic Seasonal Less << Phase 2 Completed - Canada, Ontario ... More >> Kingston, Ontario, Canada Less <<
NCT00974571 - Completed - -
NCT01134328 Allergic Conjunctivitis Phase 2 Completed - United States, Massachusetts ... More >> Ora, Inc Andover, Massachusetts, United States, 01810 Less <<
NCT01495338 Normal Ocular Health Phase 1 Completed - United States, Massachusetts ... More >> Andover Eye Associates Andover, Massachusetts, United States, 01810 Less <<
NCT03167216 Chronic Prostatitis With Chron... More >>ic Pelvic Pain Syndrome Less << Early Phase 1 Recruiting June 30, 2021 United States, Illinois ... More >> Northwestern Medical Faculty Foundation Recruiting Chicago, Illinois, United States, 60611 Principal Investigator: Praveen Thumbikat, PhD Less <<
NCT01825655 Pruritus Phase 4 Terminated(Unable to recruit p... More >>atients) Less << - United States, Virginia ... More >> Children's Hospital of Richmond at VCU Richmond, Virginia, United States, 23298 Less <<
NCT00974571 Perennial Allergic Rhinitis Phase 3 Completed - -
NCT01825655 - Terminated(Unable to recruit p... More >>atients) Less << - -
NCT00474890 Atopy Rhiniti... More >>s Less << Not Applicable Completed - Germany ... More >> Fraunhofer Institute for Toxicology and Experimental Medicine Hannover, Germany, 30625 Less <<
NCT02451579 Actinic Keratoses Not Applicable Completed - United States, California ... More >> Cosmetic Laser Dermatology San Diego, California, United States, 92121 Less <<
NCT00851344 Rhinitis, Allergic, Seasonal Phase 2 Completed - Germany ... More >> GSK Investigational Site Hannover, Niedersachsen, Germany, 30625 Less <<
NCT02447393 Dermatitis Phase 1 Completed - Japan ... More >> GSK Investigational Site Kagoshima, Japan, 890-0081 Less <<
NCT00972504 Rhinitis, Allergic, Seasonal Phase 2 Completed - Germany ... More >> GSK Investigational Site Hannover, Niedersachsen, Germany, 30625 Less <<
NCT00291642 - Completed - -
NCT00972504 - Completed - -
NCT00257595 Rhinitis, Allergic, Perennial Phase 3 Completed - -
NCT00420082 Seasonal Allergic Rhinitis Phase 2 Completed - Austria ... More >> Allergy Center Vienna West Vienna, Austria, A-1150 Less <<
NCT02543346 Allergic Rhinitis Phase 4 Completed - United States, Texas ... More >> Biogenics Research Chamber San Antonio, Texas, United States, 78229 Canada, Ontario Kingston General Hospital Kingston, Ontario, Canada, K7L 2V7 Less <<
NCT00240032 Multiple Sclerosis Phase 4 Completed - -
NCT01103050 Allergic Rhinitis Phase 2 Completed - Canada ... More >> Novartis Investigative Site Ontario, Canada Less <<
NCT00544388 Rhinitis, Allergic, Seasonal Phase 3 Completed - -
NCT02173249 Healthy Phase 1 Completed - United States, Massachusetts ... More >> Andover Eye Associates Andover, Massachusetts, United States, 01810 Less <<
NCT00253058 Rhinitis, Allergic, Perennial Phase 3 Completed - -
NCT03192488 Exercise Intolerance at Altitu... More >>de Less << Phase 4 Recruiting May 31, 2018 United States, Indiana ... More >> Indiana University Recruiting Bloomington, Indiana, United States, 47401 Contact: Robert Chapman, PhD    812-856-2452    rfchapma@indiana.edu Less <<
NCT00257569 Dermatitis, Atopic Phase 3 Completed - -
NCT01651871 Seasonal Allergic Rhinitis Phase 2 Completed - -
NCT00334698 Seasonal Allergic Rhinitis Not Applicable Completed - Germany ... More >> Fraunhofer-Institute of Toxicology and Experimental Medicine Hannover, Germany, 30623 Less <<
NCT01881113 Allergic Conjunctivitis Phase 3 Completed - United States, Massachusetts ... More >> Ora, Inc. Andover, Massachusetts, United States, 01810 Less <<
NCT01322282 Allergy Phase 1 Completed - Canada, Quebec ... More >> Algorithme Pharma Inc. Mount-Royal, Quebec, Canada, H3P 3P1 Less <<
NCT01748344 Seasonal Allergic Rhinitis Phase 2 Completed - Austria ... More >> Vienna Clinical Site Vienna, Austria Less <<
NCT01881113 - Completed - -
NCT01127620 Perennial Allergic Rhinitis Phase 3 Completed - -
NCT01551056 Allergic Conjunctivitis Phase 3 Completed - United States, Massachusetts ... More >> Ora, Inc. Andover, Massachusetts, United States, 01810 Less <<
NCT01685242 - Completed - -
NCT01551056 - Completed - -
NCT01685242 Allergic Conjunctivitis Phase 3 Completed - United States, Massachusetts ... More >> Andover Eye Associates Andover, Massachusetts, United States, 01810 Less <<
NCT00490204 Rhinitis, Allergic, Perennial PHASE3 COMPLETED 2007-10-03 GSK Investigational Site, Chib... More >>a, 277-0882, Japan|GSK Investigational Site, Fukuoka, 807-0856, Japan|GSK Investigational Site, Fukuoka, 811-1201, Japan|GSK Investigational Site, Fukuoka, 819-0002, Japan|GSK Investigational Site, Hokkaido, 001-0923, Japan|GSK Investigational Site, Hokkaido, 007-0840, Japan|GSK Investigational Site, Hokkaido, 053-0833, Japan|GSK Investigational Site, Hokkaido, 061-1133, Japan|GSK Investigational Site, Hokkaido, 061-1448, Japan|GSK Investigational Site, Hokkaido, 062-0034, Japan|GSK Investigational Site, Kanagawa, 212-0027, Japan|GSK Investigational Site, Kanagawa, 213-0011, Japan|GSK Investigational Site, Kanagawa, 216-0002, Japan|GSK Investigational Site, Kanagawa, 222-0011, Japan|GSK Investigational Site, Kanagawa, 224-0003, Japan|GSK Investigational Site, Kanagawa, 232-0056, Japan|GSK Investigational Site, Kumamoto, 862-0952, Japan|GSK Investigational Site, Kumamoto, 862-0962, Japan|GSK Investigational Site, Oita, 870-0021, Japan|GSK Investigational Site, Saitama, 333-0861, Japan|GSK Investigational Site, Saitama, 336-0022, Japan|GSK Investigational Site, Saitama, 350-1205, Japan|GSK Investigational Site, Saitama, 355-0062, Japan|GSK Investigational Site, Shizuoka, 420-0803, Japan|GSK Investigational Site, Shizuoka, 422-8066, Japan|GSK Investigational Site, Shizuoka, 436-0058, Japan|GSK Investigational Site, Tokyo, 157-0067, Japan|GSK Investigational Site, Tokyo, 170-0005, Japan Less <<
NCT03047278 Neuropathic Pain ... More >> Type 2 Diabetes Mellitus Diabetic Neuropathy, Painful Less << Phase 4 Enrolling by invitation July 1, 2019 -
NCT00257582 Pruritus Phase 3 Completed - -
NCT00751218 Urticaria Phase 4 Completed - -
NCT00637455 Seasonal Allergic Rhinitis Phase 4 Completed - United States, New Jersey ... More >> Sanofi-Aventis Bridgewater, New Jersey, United States, 08807 Less <<
NCT00504933 Seasonal Allergic Rhinitis Phase 3 Completed - -
NCT02756624 Healthy Subjects Phase 3 Completed - United States, Massachusetts ... More >> Ora Clinical Site Network Andover, Massachusetts, United States, 01810 Less <<
NCT02756624 - Completed - -
NCT00881127 Allergies Phase 1 Completed - -
NCT00150761 Anti-allergic Agents Phase 4 Completed - -
NCT01622283 Rhinitis, Allergic, Perennial ... More >>and Seasonal Less << Phase 1 Completed - Japan ... More >> GSK Investigational Site Kagoshima, Japan, 890-0081 Less <<
NCT00488176 Seasonal Allergic Rhinitis Phase 4 Unknown December 2013 Poland ... More >> Department of Pediatrics and Allergy, Medical University of Lodz Lodz, Poland Recruiting Lodz, Poland, 93-513 Contact: Violetta Ścibiorek, MD    00 48 42 689 59 72    alergol@kopernik.lodz.pl    Principal Investigator: Iwona Stelmach, MD, PhD, Prof Less <<
NCT00751166 Urticaria Phase 4 Terminated(Study could not be ... More >>re-supplied with study medication in a timely manner.) Less << - -
NCT01332188 Allergic Conjunctivitis Phase 2 Phase 3 Completed - United States, Massachusetts ... More >> Ora, Inc. Andover, Massachusetts, United States, 01810 Less <<
NCT00375713 - Completed - -
NCT00881634 Allergies Phase 1 Completed - -
NCT01332188 - Completed - -
NCT00779116 Allergies Phase 4 Completed - -
NCT00649857 Healthy Phase 1 Completed - United States, Texas ... More >> Novum Pharmaceutical Research Services Houston, Texas, United States, 77042 Less <<
NCT00779116 - Completed - -
NCT00780403 Allergies Phase 4 Completed - -
NCT00826943 Allergic Rhinitis Phase 4 Completed - United States, Tennessee ... More >> Vanderbilt University Asthma, Sinus, and Allergy Clinic Nashville, Tennessee, United States, 37203 Less <<
NCT00780403 - Completed - -
NCT00794495 Seasonal Allergic Rhinitis ... More >> Perennial Allergic Rhinitis Less << Phase 4 Completed - -
NCT00375713 Dermatitis Ec... More >>zema Less << Phase 3 Completed - Korea, Republic of ... More >> Gyeunggi-do, Korea, Republic of Kyeonggi-Do, Korea, Republic of Seoul, Korea, Republic of Less <<
NCT00650065 Healthy Phase 1 Completed - United States, Texas ... More >> Novum Pharmaceutical Research Services Houston, Texas, United States, 77042 Less <<
NCT00794846 Seasonal Allergic Rhinitis ... More >> Perennial Allergic Rhinitis Less << Phase 4 Completed - -
NCT00639587 Rhinitis, Allergic, Perennial Phase 3 Completed - -
NCT02132169 Atopic Disease (Including Alle... More >>rgic Conjunctivitis) Less << Phase 3 Completed - United States, Massachusetts ... More >> Ora, Inc. Andover, Massachusetts, United States, 01810 Less <<
NCT00826943 - Completed - -
NCT00794599 Seasonal Allergic Rhinitis ... More >> Perennial Allergic Rhinitis Less << Phase 4 Completed - -
NCT01916226 Rhinitis, Allergic, Perennial ... More >>and Seasonal Less << Phase 4 Completed - -
NCT00794378 Allergic Rhinitis Phase 3 Completed - -
NCT00794794 Allergic Rhinitis Phase 3 Completed - -
NCT00776022 Healthy Not Applicable Completed - United States, Maryland ... More >> Bioanalytical Systems, Inc Baltimore, Maryland, United States, 21201 Less <<
NCT00776139 Healthy Not Applicable Completed - United States, Maryland ... More >> Bioanalytical Systems, Inc. Baltimore, Maryland, United States, 21201 Less <<
NCT00864279 Healthy Phase 1 Completed - United States, North Carolina ... More >> AAIPharma Inc.- AAI Clinic Morrisville, North Carolina, United States, 27560 Less <<
NCT00863902 Healthy Phase 1 Completed - United States, North Carolina ... More >> AAIPharma Inc.- AAI Clinic Morrisville, North Carolina, United States, 27560 Less <<
NCT01781507 Allergic Rhinitis ... More >> Asthma Less << Phase 4 Completed - United States, California ... More >> California Allergy and Asthma Medical Group Los Angeles, California, United States, 90025 Less <<
NCT02132169 - Completed - -
NCT03340740 Allergic Rhinitis ... More >> Asthma Less << Phase 4 Recruiting December 31, 2018 United States, New York ... More >> Jacobi Medical Center Recruiting Bronx, New York, United States, 10461 Contact: Stephen Blumberg, MD    718-918-5826    stephen.blumberg@nychhc.org    Contact: Katherine Huston, MD    718-918-5875    hustonk@nychhc.org Less <<
NCT02932774 Allergic Rhinitis ... More >> Hay Fever SAR Rhinitis, Allergic, Seasonal Less << Phase 4 Completed - -
NCT01064102 Healthy Phase 1 Completed - -
NCT02865018 Neuromyelitis Optica Phase 1 Phase 2 Completed - United States, New York ... More >> Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 Less <<
NCT01916226 - Completed - -
NCT01064115 Healthy Phase 1 Completed - -
NCT03772158 Allergy Phase 1 Recruiting February 3, 2019 Canada, Quebec ... More >> Algorithme (An altascience Company) Recruiting Mount-Royal, Quebec, Canada, H3P 3P1 Contact: Bich-Chau Le    +1 (514) 858-6077 ext ext. 3236    Bich-Chau@altasciences.com    Principal Investigator: Eric Sicard, MD Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.57mL

0.51mL

0.26mL

12.86mL

2.57mL

1.29mL

25.71mL

5.14mL

2.57mL

References

 

Historical Records

Categories